Review of Immune Therapies Targeting Ovarian Cancer
| Autor: | Cong Ava Fan, Dana M. Roque, Jocelyn Reader |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty T-Lymphocytes medicine.medical_treatment Programmed Cell Death 1 Receptor Ipilimumab Pembrolizumab Immunotherapy Adoptive B7-H1 Antigen Avelumab 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Atezolizumab Internal medicine medicine Humans CTLA-4 Antigen Pharmacology (medical) Ovarian Neoplasms business.industry Cancer Immunotherapy medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Female Microsatellite Instability Cancer vaccine Nivolumab business medicine.drug |
| Zdroj: | Current Treatment Options in Oncology. 19 |
| ISSN: | 1534-6277 1527-2729 |
| DOI: | 10.1007/s11864-018-0584-3 |
| Popis: | The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink